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Meniscal lesions in the avascular zone are still a problem in traumatology. Tissue Engineering approaches with mesenchymal stem
cells (MSCs) showed successful regeneration of meniscal defects in the avascular zone. However, in daily clinical practice, a single
stage regenerative treatment would be preferable for meniscus injuries. In particular, clinically applicable bioactive substances or
isolated growth factors like platelet-rich plasma (PRP) or bone morphogenic protein 7 (BMP7) are in the focus of interest. In this
study, the effects of PRP and BMP7 on the regeneration of avascular meniscal defects were evaluated. In vitro analysis showed that
PRP secretes multiple growth factors over a period of 8 days. BMP7 enhances the collagen II deposition in an aggregate culture
model of MSCs. However applied to meniscal defects PRP or BMP7 in combination with a hyaluronan collagen composite matrix
failed to significantly improve meniscus healing in the avascular zone in a rabbit model after 3 months. Further information of the
repair mechanism at the defect site is needed to develop special release systems or carriers for the appropriate application of growth
factors to support biological augmentation of meniscus regeneration.
1. Introduction
Meniscal lesions in the avascular zone are still an unsolved
problem. Due to the poor self-healing potential of meniscal
tissue in the inner zone, partial meniscectomy often is the
only treatment option. However, the meniscus plays an im-
portant role in the biomechanics of the knee joint concerning
force transmission, shock absorption, provision of joint,
stability, lubrication, and proprioception [1]. Consecutively,
the loss of meniscus predisposes the knee joint to degenera-
tive changes [2].
Regeneration of meniscus in the avascular zone is possi-
ble. In particular, the use of mesenchymal stem cells (MSCs)
in a Tissue Engineering approach showed improved healing
of meniscal lesions in the avascular zone in animal trials [3–
5].
However, in these models, the application of MSCs
required a two-step procedure with cell expansion between
two operations. In a hypothetical clinical use, such an ap-
proach would have high regulatory burdens and costs. Ad-
ditionally, it is still unclear how MSCs promote healing in
a Tissue Engineering approach. Besides the possibility that
MSCs serve as the repair cells themselves, it seems more than
likely that they promote regeneration by delivery of bioactive
substances like growth factors [6].
Platelet-rich plasma (PRP) is a clinically available source
for the application of growth factors [7]. Depending on the
different ways of preparation, PRP provides a huge variety
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of multiple growth factors [8]. In clinical use, PRP already
showed promising results for the regeneration of different
tissue types like rotator cuff [9] and cartilage [10, 11] and
for enhanced healing during ligament reconstruction [12].
Positive effects on meniscal healing also seem to be possible.
Additionally isolated growth factors have shown impli-
cations for healing of musculoskeletal tissue. Regarding
cartilage tissue, BMP7 showed improved proliferation of
human chondrocytes [13] and chondrogenic differentiation
of adipose tissue derived MSCs [14]. In a phase I clinical
study, it showed no dose depending toxicity when injected
into osteoarthritic knees [15]. In clinical application, BMP7
revealed improved healing of osteochondral defects of the
knee by development of hyaline cartilage-like tissue [16],
which is also present in the central avascular part of the men-
iscus.
The goal of this study was the analysis of a combination
of growth factors administered by PRP or of a single growth
factor with chondrogenic potential like BMP7 to mimic the
role of MSCs for promotion of meniscal healing in the
avascular zone. The implication of this one-step biological
augmentation on the repair capacity ofmeniscal tissue should
be evaluated. We hypothesized that PRP or BMP7 delivered
to meniscal lesions in the avascular zone with a hyaluronan
collagen composite matrix are able to improve regeneration
in standardized previously described [4, 5] animal models.
2. Materials and Methods
To ensure a lasting effect of growth factors directly at the me-
niscal lesion sites, we decided to deliver PRP or BMP7 with a
hyaluronan collagen composite matrix. This scaffold showed
positive characteristics as a carrier for biological augmenta-
tion in previous studies [3–5, 17].
2.1. Composite Scaffolds. The sponge scaffolds were manufac-
tured from70%derivatized hyaluronan-ester and 30% gelatin
as described previously [17, 18]. The hyaluronan component
was obtained from the commercially available product Ja-
loskin (Fidia Advanced Biopolymers, Abano Terme, Italy),
which is manufactured from hyaluronate, highly esterified
with benzyl alcohol on the free carboxyl groups of glucu-
ronic acid along the polymer. The gelatin component was
hydrolyzed bovine collagen type I (Sigma, Taufkirchen, Ger-
many).
The porous scaffolds were manufactured by the solvent
casting, particulate leaching technique, usingNaClwith grain
size of 250–350 𝜇m as primary porogen. Additionally, the
insufflating air which replaced the evaporating solvent gen-
erated secondary pores with the size of 50–100𝜇m. Scaffolds
had a diameter of 2.2mm and a height of 3mm.
2.2. In Vitro PRP Analysis. For in vitro analysis of growth fac-
tor release kinetics, hyaluronan collagen composite scaffolds
were seeded with prepared human PRP. Because of the re-
quired amount of blood and the subsequent potential clini-
cal use, we decided to analyze release kinetics with human
PRP.The growth factormatrix composites were cultured over
a period of 8 days and the release of PDGF, TGF𝛽1, andVEGF
was measured over time.
2.3. Preparation of Human PRP and Loading of Composite
Scaffolds. For the in vitro analysis of PRP, human blood was
drawn from 4 volunteers with the approval of the local ethical
committee. Clotting was prevented with citrate and ACD-
A. 10mL blood was spun down unrestrained at 200G for
15 minutes and after removal of the erythrocytes-layer again
at 4000G for 15 minutes. The platelet-rich cell pellet was
isolated by removal of the plasma [19].
In pretests, microscopical analysis and thrombocytes/cell
counts were performed to assess the quality and compo-
sition of the pellets and the concentration of thrombo-
cytes. To assess viability of the isolated thrombocytes, the
standard procedure of a life-dead kit (LIVE/DEAD Viabil-
ity/Cytotoxicity Kit (L-3224), Mo Bi Tec, Go¨ttingen) had
to be modified as thrombocytes lack sufficient quantity of
DNA or RNA to detect dead cells. Therefore, vital cells were
stained with calcein AM and a photo was taken under the
fluorescencemicroscope. Another picture of the same section
was taken under transmitted light in order to count the
total number of cells. Both pictures were put together and
transparence reduced to 50% each. The number of vital cells
was subtracted from all cells to get the number of dead cells.
For further analysis, hyaluronan collagen composite
matrices were seeded with PRP by soaking the buffy coat into
the scaffolds.
2.4. In Vitro Analysis of Growth Factor Release Kinetics. Four
PRP hyaluronan collagen composite matrix constructs of
each of the 4 volunteers were cultured in vitro over a period
of 8 days in 1mL autologous plasma.
Concentrations of the growth factors PDGF, TGF𝛽1, and
VEGF were measured by ELISA technique at 0 h, 8 h, 12 h,
24 h, 48 h, and 192 h (8 days) using kits from R&D Systems:
Human PDGF-AB DuoSet (DY222), Human TGF𝛽1 DuoSet
(DY240), and Human VEGF DuoSet (DY293B). Results of
cultured empty control scaffolds were subtracted from the
growth factor concentrations obtained from the cultured
PRP loaded scaffolds in order to exclude an influence of the
remaining small growth factor activity in the autologous plas-
ma.
2.5. In Vitro BMP7 Analysis. The effect of BMP7 on chondro-
genesis was tested to evaluate the potential use of this isolated
growth factor for regeneration in the cartilaginous avascular
part of the meniscus. For this analysis, the aggregate culture
chondrogenesis model with MSCs of rabbits described by
Johnstone et al. [20, 21] was used. After preparation of the
MSCs, the pellets were cultured in vitro in chondrogenic
medium with different concentrations of BMP7. Chondroge-
nesis was measured by a collagen II ELISA.
2.6. Bone Marrow Harvest and Culture. The bone marrow
harvest and cell isolation of MSCs were performed as de-
scribed elsewhere [20]. Marrow derived cells were harvested
from the iliac crest of New Zealand White Rabbits and
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collected into a heparinized syringe. Dulbecco’s modified
Eagle’s medium (DMEM), low glucose concentration, with
10% fetal bovine serum, 1% penicillin, and 1% Hepes was
added to the aspirate. Nucleated cells (20×106) were plated in
75 cm2 culture dishes and cultivated at 37∘C.Themediumwas
changed twice a week until the adherent cells reached 80%
confluence.
2.7. In Vitro Chondrogenic Differentiation. In vitro chondro-
genesis was performed according to recently published pro-
tocols [17, 20]. Expanded MSCs were trypsinized, and aggre-
gates of 2 × 105 cells were formed through centrifuga-
tion at 2000 RPM for 5 minutes in V-bottomed 96-well
plates. Chondrogenic differentiation was induced by treat-
ment with serum-free high-glucose DMEM (Gibco, Invitro-
gen) containing 100 nM dexamethasone (Sigma, Steinheim,
Germany), 1% ITS 3 (insulin-transferrin-selenium solution)
(Sigma), 200𝜇ML-ascorbic acid 2-phosphate (Sigma), 1mM
sodium pyruvate (Gibco Invitrogen), and 10 ng/mL human
TGF𝛽1 (R&D Systems, Wiesbaden, Germany). Culture time
was 21 days.
For analysis of the influence of BMP7 on the chondrogen-
esis of MSCs of rabbits, 5, 10, 50, 100, or 200 ng/mL BMP7
(generous gift from Genera Biotech, Zagreb, Croatia) was
added with or without 10 ng/mL TGF𝛽1 to the culture medi-
um.
2.8. Collagen II ELISA Analysis for Chondrogenic Differen-
tiated MSC Aggregates. An enzyme-linked immunosorbent
assay test for collagen II was performed on chondrogenically
differentiated MSC aggregates. Pellets were homogenized in
0.05M acetic acid plus 0.5M NaCl (pH 2.9-3.0), digested
with 10mg/mL pepsin dissolved in 0.05M acetic acid on the
rotator for 48 hours at 4∘C.The further steps of digestion and
the collagen type II estimation were performed as described
in the Native Type II Collagen Detection Kit 6009 protocol
(Chondrex, Redmond, WA, USA). The DNA concentration
in collagen digests was assayed using theQuant-iT PicoGreen
dsDNA Assay Kit (Invitrogen, Eugene, OR, USA). Collagen
type II was determined as a ratio between content of Collagen
type II and DNA for each pellet.
2.9. In Vivo Analysis of the Effects of Applied PRP or BMP7 on
Meniscal Lesions in the Avascular Zone. Harvest of platelet-
rich plasma and loading of composite scaffolds for the animal
trial: for the animal trail, autologous blood (10mL) was
drawn from the anesthetized rabbit’s ear vein.This procedure
was approved by the Local Institution of Animal Care. The
preparation of the PRP and the seeding of the scaffolds were
done according to the human protocol described above.
2.10. Surgical Procedure for Meniscus Defects. The rabbit
animal models were already described and are validated
standardized models for testing of meniscal treatment in the
avascular zone [3–5]. Similar to human meniscus untreated
or only sutured lesions in the avascular zone show no ten-
dency for healing.The procedures were approved by the Insti-
tutional Animal Care and Use Committee of our institution.
24 New Zealand White rabbits (five-month-old males)
were used for the in vivo PRP analysis. The rabbits were
anesthetized and exposure of the lateral joint compartment
was achieved by a lateral parapatellar arthrotomy. Avascular
meniscal defects were made by using a 2mm punch device
(Stiefel, Offenbach am Main, Germany) (12 rabbits) or by
inserting a 4mm long longitudinal meniscal tear in the avas-
cular zone (12 rabbits).The punch defects were treated with a
hyaluronan collagen composite matrix loaded with PRP. The
meniscal tearswere treated by aPRP seeded compositematrix
and a 5–0 PDS outside-in suture. This procedure was done
bilaterally, with the contralateral knee serving as control; an
empty hyaluronan-gelatin scaffold was the control implant
for all rabbits. Postoperatively, the animals were allowed free
movementwithout use of any type of immobilization. Rabbits
started full weight bearing immediately after recovery from
anesthesia.The animals were sacrificed at 6 or 12 weeks. Each
group consisted of six New Zealand White rabbits.
For the in vivo evaluation of BMP7 effects on meniscal
healing, 12 animalswere used.A 2mmcircular shapedmenis-
cal defect in the avascular zone was inserted and treated with
a hyaluronan collagen composite matrix and an additional
injection of 1 𝜇g BMP7 at the time of implantation (Group
1, 6 rabbits). In another group, the defect was filled with
a 14-day precultured construct of MSCs and a hyaluronan
collagen composite matrix (Group 2, 6 rabbits). Harvesting
of the MSCs and seeding of the scaffold was performed like
described above [5]. Each scaffold was seeded with 1.5 × 106
MSCs.The chondrogenic medium consisted of DMEM (high
glucose), 200𝜇M ascorbic acid 2-phosphate, 1% ITS (both
from Sigma, Taufkirchen, Germany), 1mM pyruvate, 100 nM
dexamethasone, 10 ng/mLTGF𝛽1 (R&D systems,Wiesbaden,
Germany), and 50 ng/mL BMP7. The implantation of a cell-
free hyaluronan collagen compositematrix in a 2mmcircular
avascular defect in the lateral meniscus of the contralateral
side served as a control group. Follow-up period was 3
months.
2.11. Gross Assessment of Joint Morphology. Rabbits with
surgical implants were euthanized for tissue harvest with
an overdose of pentobarbital (1600mg/mL) given intraperi-
toneally. After exposure of the knee joint, the macroscopic
morphology of the meniscus and the attachments of the
meniscus to the tibial plateau were evaluated and photo-
graphed.
2.12. Histology. The lateralmenisci harvested from the in vivo
experiments were fixed in 4% phosphate buffered parafor-
maldehyde embedded in Tissue-Tek O.C.T. and frozen in
liquid nitrogen. Ten-micrometer radial sections of all samples
were produced and every fifth of themwas stained with tolui-
dine blue or DMMB.
2.13. Immunohistochemistry. As the pars intermedia of rab-
bit’s meniscus contains mainly collagen type II, especially
towards the avascular central part of the meniscus, the im-
munohistochemical analysis was performed for collagen type
II. Sections were washed and then digested for 15min with
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Table 1: Scoring system for the evaluation of the quality of meniscal repair tissue.
0 1 2 3
Defect filling No fill <25% 25–75% >75%
Surface No surface ruptured Fissured/fibrillated Meniscus-like
Integration No integration Partial, unilateralintegration
Bilateral partial or
unilateral complete
integration
Bilateral complete
integration
Cellularity No cells >10 cell clusters/slide No cell cluster/slide,cell-ECM-ratio >0,5
Meniscus-like
cell-ECM-ratio
Cell morphology No cells <25% meniscus-likecells 25–75% meniscus-like cells
>75% meniscus-like
cells
Content of
proteoglycan
No staining for
proteoglycan <25% 25–75% >75%
Content of collagen II No staining forcollagen II <25% 25–75% >75%
Stability No stability Weak Stable in shape Stable to pressure andpulling stress
ECM: extracellular matrix.
0.1% pepsin at pH 3.5 to facilitate antibody access to the
target epitopes. Type II collagen was immunolocalized by
the immunoperoxidase ABC technique (Vector, Burlingame,
CA, USA), applying monoclonal primary antibodies ms. anti
collagen II, clone II-4C11 (Calbiochem-Merck, Schwalbach,
Germany), biotin conjugated polyclonal secondary antibod-
ies (goat anti-mouse IgG (Jackson, West Grove, PA, USA)),
and the nickel and cobalt enhanced DAB stain visualization.
2.14. Meniscus Scoring System. In order to compare the mac-
roscopical, histological, and immunohistochemical results
after repair of the meniscal lesions, a validated meniscus
scoring systemwas used, which was developed and published
for the evaluation of meniscal defects [4, 5]. Subgroups in
macroscopical assessment were “stability” and “defect filling
with repair tissue” and for histological analysis the “quality of
the surface area,” “integration,” “cellularity,” and “cell mor-
phology” and subgroup for immunohistochemical character-
ization was the “expression of proteoglycan and moderate
collagen type II in the repair tissue.”The repair was graded by
summing up the scores from 0 to 3 of eight individual sub-
groups. Consequently, the final scores were between 0 points
(no repair) and maximal 24 points (complete reconstitution
of the meniscus) (Table 1). The data was collected from 2
blinded scorers, both experienced in knee anatomy of rabbits
and in histological assessment.
2.15. Statistical Analysis. For the in vitro BMP7 evaluation,
independent unpaired t-tests were performed to compare the
different collagen II ELISA groups. For the in vivo testing, the
scoring results of each group were compared to the results of
the control group (cell-free hyaluronan collagen composite
matrix on the contralateral side). Paired t-tests were done
for the analysis of the scoring results of all groups. For all
evaluations, the level of statistical significance was set at a
probability value of less than 0.05.
3. Results
3.1. In Vitro Analysis of PRP. Human PRP seeded in hyaluro-
nan collagen composite matrices resulted in a high number
of vital thrombocytes (94%). The PRP was leukocyte-poor
with an average of 2,5 × 107 platelets/𝜇L and a 3 times higher
concentration of thrombocytes compared to the correspond-
ing blood samples. After seeding of the composite matrix,
an equal distribution of the thrombocytes throughout the
scaffold was obtained (data not shown).
To imitate the joint environment, the PRP/hyaluronan
collagen composite matrix constructs were cultured for 8
days in autologous plasma. The results of the ELISA analysis
showed a constant increase in PDGF and TGF𝛽1 from day 0
to day 8 indicating that growth factors were released over the
whole follow-up period. No VEGF was detectable over the
period of 8 days (Figure 1).
3.2. InVivoAnalysis of theMeniscal Treatment in theAvascular
Zone with PRP. The implantation of a hyaluronan collagen
composite matrix loaded with PRP showed no significant
improvement of the repair of avascular meniscal punch
defects compared to an implantation of a cell-free scaffold.
After 6 and 12 weeks, the lesions were only partially filledwith
fibrous-like scar tissue. Tears in the tip of the native meniscus
could often be detected (Figures 2(a), 2(b), and 2(c)).
In the control group, repair of the punch defects with cell-
free matrices resulted in partial defect filling in half of the
animals after 6 weeks and also after 12 weeks (Figures 2(d),
2(e), and 2(f)). Macroscopically, the repair tissue was soft and
only partially integrated. Microscopically, the punch defects
were partially filled with fibrous and cell-rich scar tissue.
No residuals of the implanted scaffolds could be detected
(Figure 3).
Regarding the meniscus tear model, a significant better
repair of avascular meniscal tears could be detected after
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Figure 1: Release kinetics of the growth factors TGF𝛽1, PDGF, and
VEGF from PRP hyaluronan collagen composite matrix constructs
over a period of 8 days cultured in rabbits’ autologous plasma (mean
values of 4 volunteers with standard deviation).
treatment with PRP seeded matrices compared to the cell-
free matrices after 6 weeks (𝑃 < 0,05). However, this positive
effect of PRP was not significant after 3 months mainly due to
a high inter-animal variability. Defect filling with constructs
containing matrices with PRP resulted in a poor tear filling
without regeneration of the meniscal tear after 3 months. In
a few cases, muted instable fibrous attachments between the
two parts of the meniscus could be detected (Figures 2(g),
2(h), and 2(i)).No signs ofmeniscus-like tissue reconstitution
could be seen (Figures 2(j), 2(k), and 2(l)). In contrast to
complete empty tears in the control group, this mutant repair
tissue was responsible for the improved scores (Figure 4).
3.3. In Vitro Analysis of BMP7. All tested BMP7 concentra-
tions, added to chondrogenic medium with TGF𝛽1, revealed
chondrogenic differentiation of MSCs. The addition of
50 ng/mL BMP7 showed the best results regarding chondro-
genesis in the pellet culture model with the highest content
of collagen II in the ELISA analysis. The addition of higher
concentrations of BMP7 showed no beneficial effect on the
development of collagen II under TGF𝛽1 medium condition.
In culture condition without TGF𝛽1, BMP7 showed a
concentration dependent increase in collagen II deposition
but less chondrogenic differentiation compared to TGF𝛽1
containing conditions (Figure 5).
3.4. In Vivo Analysis of the Influence of BMP7 on the Regen-
eration of Meniscal Defects. The additional injection of 1 𝜇g
BMP7 in meniscus lesions at the time of treatment of a
circular avascular meniscal defect with cell-free hyaluronan
collagen composite matrices (group 1) showed no beneficial
effect compared to matrix implantation without BMP7 injec-
tion (control). After 3 months in vivo, only mixed tissue with
scar and small-differentiated areas (collagen type II positive)
were detectable in the BMP7 treated meniscal defects and
in the control defects (Figures 6(a)–6(f)). However, the
defects treated with MSC composite matrix constructs and
precultured in a BMP7 and TGF𝛽1 containing chondrogenic
medium showed superior meniscal scoring results compared
to the cell-free matrices (Figure 7). In defects treated with
preculturedMSCmatrix constructs, differentiatedmeniscus-
like repair tissue was detectable after 3 months in vivo. In
contrast, the treatment with a cell-free composite matrix
showed only fibrous defect filling after 3 months in vivo
(Figures 6(g)–6(i)).
4. Discussion
The study analyzed the effects of PRP on meniscus regener-
ation in two different meniscus defect models. PRP seeded
hyaluronan collagen composite matrices failed to repair a cir-
cular full size meniscal defect as well as meniscus tears in the
avascular zone. After 3months, the local injection of BMP7 in
composite matrices for treatment of circular meniscal defects
in the avascular zone showed no improvement of meniscus
regeneration compared to treatment with compositematrices
without BMP7. Only treatment with constructs of autologous
MSCs seeded on a hyaluronan collagen composite matrix
showed improvement of meniscal healing and defect filling
with differentiated meniscus-like tissue after 3 months in
vivo. Nevertheless, growth factors are still in the focus of a
potential clinical use for biological augmentation of menis-
cus treatment as they provide the possibility of a one-step
procedure.
Tissue Engineering is a promising therapy option for
the treatment of meniscal lesions especially in the avascular
zone. Recent studies showed that MSCs are able to fill avas-
cular meniscal defects with differentiated repair tissue [3–
5]. However, these approaches require a two-step procedure
with the need of cell expansion between two operations. Such
approaches would have high regulatory burdens and costs in
daily clinical practice.
Additionally, it is still unclear howMSCs promote menis-
cal healing. Caplan and Dennis [6] described a dual role of
MSCs in musculoskeletal regeneration. On the one hand,
MSCs could differentiate into repair cells that are required
at the defect site. On the other hand, MSCs could act as a
mediator for bioactive substances and secrete, for example,
growth factors. So it seems very likely that the use of
growth factors only could have similar positive effects on the
regeneration ofmeniscus tissue compared to a stem cell based
approach by mimicking the delivery of bioactive substances.
PRP represents an easy available source for a combination
of multiple growth factors that is already in clinical use
and can be applied in a one-step procedure. Properties like
“biological glue,” contribution to coagulation and hemostasis,
intra-articular restoration of hyaluronic acid, anti-inflamma-
tion, and pain relief are described [7].
Beneficial effects by clinical use of PRPwere seen in treat-
ment of rotator cuff tears [9], Achilles tendon ruptures [22],
chronic tendinosis [23], muscle injuries [7], ACL-rupture
[12], and cartilage defects [11, 24].
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(g) (h) (i)
(j) (k) (l)
Figure 2: Gross morphology and histological and immunohistochemical (collagen type II) analysis 3 months after treatment of a meniscal
punch defect with a PRP hyaluronan collagen composite matrix construct (a, b, and c) or an emptymatrix (control) (d, e, and f) and 3months
after treatment of meniscal tears with a PRP hyaluronan collagen composite matrix construct (g, h, and i) or an empty matrix (j, k, and l). No
improvement by treatment of meniscal lesions with PRP could be detected. Magnification bars: (a, d, g, and j): 10mm; (b, c, e, f, h, i, k, and
l): 1mm.
Different techniques were described to prepare PRP. The
quality and composition of the PRP depend on the speed
and number of centrifugations, the use of anticoagulant or
activator, and the presence of leukocytes [7]. The PRP used
in this study was leukocyte-poor so that a described dele
terious effect from matrix metalloproteinases 8 and 9 from
the neutrophils in the PRP [25] could be neglected. The
number of platelets in the PRP is essential for their bio-
logical potential. For treatment of bone defects, defined
concentrations of platelets in the PRP are described for
optimal effects on bony regeneration [26]. However, there
are no data in literature that evaluated the most effective
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Figure 3: Results of the scoring of meniscal repair tissue after
6 weeks and 3 months in vivo. No significant improvement by
treatment of a meniscal punch defect with PRP could be detected
compared to the control group (∗𝑃 ≤ 0,05).
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Figure 4: Results of the scoring of meniscal repair tissue after 6
weeks and 3 months in vivo. Significant improvement by treatment
of meniscus tears with PRP could be detected after 6 weeks
compared to the control group (∗𝑃 ≤ 0,05).
concentration of platelets and released growth factors for a
biological support of meniscus regeneration. Additionally,
in this study, the way of preparation of the PRP had to be
adapted to the rabbit model. In order to reach a high number
of active and vital thrombocytes, decision was made for an
unrestrained centrifugation with 200G for 15 minutes and
4000G for another 15 minutes with ACD-A and citrate to
inhibit coagulation. By this method, a high number of vital
thrombocytes were reached with only 10mL blood of the
rabbits.
Growth factor release was measured over a period of 8
days. In order to imitate the synovial fluid environment of
the knee, the PRP hyaluronan collagen composite matrix
constructs were cultured in rabbits’ autologous plasma. Con-
stant release of PDGF and TGF𝛽1 that are known to enhance
differentiation and proliferation of meniscal cells [27, 28] was
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Figure 5: ELISA analysis of the collagen II content of chondrogenic
differentiatedmesenchymal stem cell (MSC) aggregates after 21 days
of culture under different conditions.The pellets were cultured with
0, 5, 10, 50, 100, or 200 ng/mL BMP7 with or without 10 ng/mL
TGF𝛽1. The addition of 50 ng/mL BMP7 to the TGF𝛽1 containing
culturemedium showed the highest content of collagen II compared
to other BMP7 concentrations with a significant difference between
10 ng/mL and 50 ng/mL BMP7 (∗𝑃 ≤ 0,05). A BMP7 concentration
dependent increase in collagen II contentwas detected under culture
conditions without TGF𝛽1.
seen over the whole measure period of 8 days. The content of
collagen type I in the composite matrix might be a possible
reason for the constant release of growth factors, as collagen
type I is known as an activator for PRP, for example, from
chitosan matrices [29]. Similar to this study, Harrison et al.
saw a constant prolonged release of growth factors compared
to other activators like thrombin when collagen type I was
used as a component of a PRP seeded scaffold [30].
However, no release of VEGF was detectable over 8 days.
While other authors report a high concentration of VEGF in
the PRP [8], recently, Anitua et al. also saw a fast decrease
in VEGF release from their PRP matrix [31]. The differ-
ent methods of preparation or presence of soluble VEGF
receptors from remaining leukocytes [31] might be possible
reasons for the varying amounts of VEGF. Theoretically, a
highly angiogenic growth factor like VEGF [32] might have a
positive effect on the regeneration of an avascular tissue like
the inner zone of the meniscus. However, there are reports
that VEGF coated PDLLA sutures failed and showed even
worse results than uncoated sutures when meniscal tears in
the avascular zone of meniscus were reconstructed in a rabbit
model [33]. So VEGF does not seem to be amandatory factor
for regeneration in the avascular zone of meniscus.
In this study, PRP delivered to an avascular meniscal
defect in combination with a hyaluronan collagen composite
matrix failed to improve meniscal healing. No sufficient
repair tissue was detectable in the circular punch defect after
6 or 12 weeks. However, Ishida et al. showed positive results in
vitro and in vivo by treatment of avascular meniscal defects
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Figure 6: Gross morphology and histological and immunohistochemical (collagen type II) analysis 3 months after treatment of a meniscal
punch defect with a cell-free hyaluronan collagen composite matrix and a single injection of 1 𝜇g BMP7 at the time of surgery (a, b, and c)
or with an empty matrix (control) (d, e, and f). Images (g, h, and i) show the results after treatment with a hyaluronan collagen composite
matrix seeded with mesenchymal stem cells (MSCs) and precultured in chondrogenic medium containing BMP7 for 14 days. Treatment with
MSCs showed the best defect filling with differentiated repair tissue. Magnification bars: (a, d, and g): 10mm; (b, c, e, f, h, and i): 1mm.
with PRP [34], but the meniscal defect size was smaller than
that in the present study.
In treatment of meniscus tears, a tendency of improved
healing with the addition of PRP to themeniscal suture could
be seen after 6 weeks; however, this effect was not significant
after 3months in vivomainly due to a high inter-animal varia-
bility. Partially stable repair tissue was detectable with the
addition of PRP, which was responsible for the higher scores
compared to complete empty tears in groups with meniscus
suture alone. Clinically, Kessler and Sgaglione [35] explored
the clinical use of PRP to augment meniscal repairs and
found successful healing along with an 80% success rate in
Tegner and Lysholm scores of 40 young patients treated with
meniscal repair and PRP. However, this clinical study was a
case series without a control group. So there is still no clear
evidence of improvement of meniscal healing with PRP, but
signs for a positive influence on meniscal regeneration.
Besides the application of a combination of multiple
growth factors with PRP, also isolated growth factors are
interesting for enhancement of meniscal repair in a clinical
one-step setting. One of these growth factors that are clini-
cally applicable is BMP7. BMP7 showed promising results for
induction of bone formation [36] but also in the field of carti-
lage therapy. So BMP7 improved the culture and proliferation
of human chondrocytes [13] and enhanced the chondrogenic
differentiation of adipose tissue derived MSCs in vitro. Cook
et al. were able to successfully treat osteochondral defects
with BMP7 injection in clinical use [16]. In this study, the
addition of BMP7 to the chondrogenic medium with TGF𝛽1
induced higher contents of collagen II in chondrogenically
differentiated aggregates of MSCs. However, high concentra-
tions of BMP7 in culture conditions without TGF𝛽1 showed
also increasing contents of collagen II deposition indicating
the highly chondrogenic potential of this growth factor.
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Figure 7: Results of the scoring of meniscal repair tissue after 3
months in vivo. Treatment with mesenchymal stem cell composite
matrix constructs showed significant repair improvement compared
to the control group (∗𝑃 ≤ 0,05).
In vivo, the local injection of BMP7 at the defect site in
addition to the insertion of a hyaluronan collagen composite
matrix showed partially differentiated repair tissue but no
significant improvement of meniscal healing in an avascular
meniscal punch defect compared to a matrix without BMP7.
In contrast, treatment of meniscal punch defects with a MSC
composite matrix construct resulted in a significant improve-
ment of meniscal healing in the avascular zone.
In this study, BMP7 was added to the chondrogenic
medium during the 14 days of preculturing period of the
MSC composite matrix constructs. As comparable results in
treatment of avascular meniscal defects were achieved with-
out the use of BMP7, in recent studies, BMP7 does not seem
to be mandatory in the preculturing period.
Limitations of the study are the rabbit animal model and
the different cell sources used in the study that make the re-
sults less comparable.
PRP and BMP7 failed to significantly improve meniscal
healing in vivo in this animalmodel. Nevertheless, short term
improvement in treatment of meniscal tears by PRP, constant
release of growth factors from a PRP seeded hyaluronan
collagen composite matrix, and support of MSCs by BMP7
are promising aspects for a possible clinical application of
growth factors to supportmeniscal treatment. As a promising
biological augmentation applicable in a one-step procedure,
growth factors still have to be in the focus of future research.
One of the actual problems for treatment with bioactive
substances like PRP or isolated growth factors might be the
uncontrolled manner of acting at the defect site. As MSCs
promotemeniscal healing, their secretion pattern of bioactive
substances has to be elucidated to be able to apply the right
growth factorswith the correct concentration at the right time
during the regeneration process. Specific release systems and
carriers will be necessary to reach that goal.
5. Conclusions
In the current study, PRP and BMP7 showed positive aspects
to promote meniscus regeneration in a one-step procedure
but failed to improve significantly meniscal healing in the
avascular zone in vivo. Uncontrolled release of growth factors
in vivo might be a possible reason. However, biological aug-
mentation for regenerative meniscal treatment in a one-step
procedure still seems to be possible. One aspect of further
investigations might be the analysis of the effective secretion
patterns of bioactive substances of MSCs to develop release
systems for a defined and specific application of growth
factors at the meniscal defect site.
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